Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880473 · ClinicalTrials.gov registry record · NA
Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment
A NA study of Gastrointestinal Complication, sponsored by Entac Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 8
- Study locations
NCT04880473: Recruiting NA study of Gastrointestinal Complication, sponsored by Entac Medical.
NCT04880473 is a NA study of Gastrointestinal Complication that is actively recruiting participants, run by Entac Medical. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04880473, a NA study of Gastrointestinal Complication, is actively recruiting participants, sponsored by Entac Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 8
- Study locations
Study Summary
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first 24 hours after surgery, a failure to successfully orally re-feed a subject is defined as presentation with emesis, requiring a reversal of diet, or the placement of a nasogastric tube on first postoperative day or later. The device is considered non-significant risk (NSR). The device does not inform medical decisions in this study. Researchers will be blinded to results of the device during this study.
Conditions Studied
Interventions
- DEVICE PrevisEA device
Study Locations (8)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Florida
- Adventist Health System/Sunbelt, Inc. d/b/a AdventHealth Orlando - Orlando
Illinois
- Northwestern University - Chicago
Michigan
- Spectrum Health Blodgett Hospital - Grand Rapids
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- The Cleveland Clinic Foundation - Cleveland
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2024-12-01 |
| Phase | NA |
What NCT04880473 shows while recruiting
NCT04880473 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Gastrointestinal Complication appearing as the primary indexed condition, and to 1 intervention - of which PrevisEA device is the first listed.
NCT04880473 lists 8 locations in 7 states (Minnesota, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT04880473 about?
NCT04880473 is a clinical study titled "Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment". PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postope...
What is the current status of trial NCT04880473?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2021-09-14. Estimated completion is 2024-12-01.
What conditions does trial NCT04880473 study?
This clinical trial studies the following conditions: Gastrointestinal Complication.
What interventions are being tested in trial NCT04880473?
The interventions under investigation include: PrevisEA device (DEVICE).
Who is sponsoring clinical trial NCT04880473?
This trial is sponsored by Entac Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04880473 being conducted?
This trial has 8 study locations across Florida, Illinois, Michigan, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Complication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04880473's enrollment target sits among peer trials
400 246th of 2000 higher than 1,734 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI